JOP20190060A1 - مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 - Google Patents
مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1Info
- Publication number
- JOP20190060A1 JOP20190060A1 JOP/2019/0060A JOP20190060A JOP20190060A1 JO P20190060 A1 JOP20190060 A1 JO P20190060A1 JO P20190060 A JOP20190060 A JO P20190060A JO P20190060 A1 JOP20190060 A1 JO P20190060A1
- Authority
- JO
- Jordan
- Prior art keywords
- compound
- glp
- receptor agonist
- salt
- agonist effect
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical group C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016187605 | 2016-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190060A1 true JOP20190060A1 (ar) | 2019-03-26 |
Family
ID=61689595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0060A JOP20190060A1 (ar) | 2016-09-26 | 2017-06-16 | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
Country Status (38)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP2021501768A (ja) * | 2017-11-02 | 2021-01-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性を有する新規の高活性なピラゾロ−ピペリジン置換インドール−２−カルボキサミド |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| CA3140972C (en) * | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| JP7360301B2 (ja) | 2019-11-08 | 2023-10-12 | Ｋｙｂ株式会社 | 作動流体供給システム |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021249492A1 (zh) * | 2020-06-10 | 2021-12-16 | 南京明德新药研发有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
| IL299704A (en) * | 2020-07-20 | 2023-03-01 | Eccogene Shanghai Co Ltd | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them |
| CR20230066A (es) * | 2020-08-06 | 2023-05-29 | Gasherbrum Bio Inc | Agonistas del glp-1 heterocíclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP2023539584A (ja) | 2020-09-01 | 2023-09-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| EP4211133A4 (en) * | 2020-09-07 | 2024-11-27 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| JP2023540609A (ja) * | 2020-09-10 | 2023-09-25 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US12454511B2 (en) * | 2020-10-08 | 2025-10-28 | Eli Lilly And Company | 6-methoxy-3,4-dihydro-1H-isoquinolin compounds |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| US20240246959A1 (en) | 2020-11-27 | 2024-07-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Benzimidazole derivative and preparation method therefor and medical use thereof |
| US20240208952A1 (en) | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| CN117098758A (zh) | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023025201A1 (zh) * | 2021-08-24 | 2023-03-02 | 南京明德新药研发有限公司 | 咪唑并环类化合物及其应用 |
| CN118948849A (zh) | 2021-09-08 | 2024-11-15 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| HRP20251161T1 (hr) | 2021-09-27 | 2025-11-21 | Terns Pharmaceuticals, Inc. | Benzimidazol karboksilne kisele kao agonisti glp-1r |
| TW202334129A (zh) | 2021-10-25 | 2023-09-01 | 美商拓臻製藥公司 | 作為ｇｌｐ—１ｒ促效劑的化合物 |
| CN119343339A (zh) * | 2022-01-24 | 2025-01-21 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| JP2025506473A (ja) * | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2023164050A1 (en) | 2022-02-23 | 2023-08-31 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| IL316629A (en) * | 2022-05-11 | 2024-12-01 | Lilly Co Eli | GLP1 drug compounds |
| WO2023220112A1 (en) | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 tablet compositions |
| JPWO2024063143A1 (enExample) | 2022-09-22 | 2024-03-28 | ||
| CN118791482B (zh) * | 2022-11-20 | 2025-09-09 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑类化合物、药物组合物及其应用 |
| AU2023404652A1 (en) * | 2022-11-28 | 2025-05-01 | The University Of Melbourne | Pharmaceutical combinations and uses thereof |
| WO2024129676A1 (en) * | 2022-12-13 | 2024-06-20 | Eli Lilly And Company | Dosage regime of orforglipron for treating a subject with type 2 diabetes (t2d), obesity, or overweight with at least one weight related comorbidity |
| KR20250121439A (ko) | 2022-12-19 | 2025-08-12 | 일라이 릴리 앤드 캄파니 | Glp1 ra 및 그의 중간체의 제조 방법 |
| EP4652167A1 (en) * | 2023-01-17 | 2025-11-26 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| IL322686A (en) | 2023-02-16 | 2025-10-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
| TW202502322A (zh) * | 2023-06-29 | 2025-01-16 | 大陸商韋恩生物科技有限公司 | 一種glp-1受體激動劑及其製備方法和用途 |
| CN120574223B (zh) * | 2023-06-30 | 2025-11-18 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物 |
| WO2025011664A1 (zh) * | 2023-07-12 | 2025-01-16 | 歌礼制药(中国)有限公司 | Glp-1r激动剂的制剂及其制备方法 |
| AR133241A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| TW202521528A (zh) | 2023-07-13 | 2025-06-01 | 美商雅空嘉閣生物公司 | 化合物、組合物及方法 |
| WO2025026270A1 (zh) * | 2023-07-28 | 2025-02-06 | 上海翰森生物医药科技有限公司 | 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025057134A2 (en) * | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
| WO2025097835A1 (zh) | 2023-11-10 | 2025-05-15 | 重庆医药工业研究院有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| WO2025103443A1 (zh) * | 2023-11-16 | 2025-05-22 | 海思科医药集团股份有限公司 | 一种咪唑-2-酮衍生物及其在医药上的应用 |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| WO2025131043A1 (zh) * | 2023-12-22 | 2025-06-26 | 石药集团百克(山东)生物制药股份有限公司 | 一类多环化合物及其用途 |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
| KR20250102249A (ko) | 2023-12-27 | 2025-07-07 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2025148997A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种四氢吡啶并吡唑衍生物及其在医药上的应用 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025162065A1 (zh) * | 2024-01-30 | 2025-08-07 | 海创药业股份有限公司 | 一种具有glp-1受体激动剂作用的小分子化合物及其用途 |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025176130A1 (zh) * | 2024-02-19 | 2025-08-28 | 上海壹迪生物技术有限公司 | 一种含吡唑并环类化合物、其药物组合物及其用途 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2025237355A1 (zh) * | 2024-05-17 | 2025-11-20 | 成都地奥九泓制药厂 | 一种glp-1受体激动剂化合物、其制备方法及其应用 |
| CN119101040B (zh) * | 2024-11-08 | 2025-03-21 | 杭州澳赛诺医药技术有限公司 | 一种通过去对称化合成芳基取代的手性四氢吡喃环的方法 |
| CN120309500B (zh) * | 2025-06-19 | 2025-08-15 | 南昌大学 | 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998438A (en) | 1996-11-26 | 1999-12-07 | Allelix Biopharmaceuticals, Inc. | 5-cyclo indole compounds |
| WO1999050262A1 (en) | 1998-04-01 | 1999-10-07 | Janssen Pharmaceutica N.V. | Pde iv inhibiting pyridine derivatives |
| CN1771231B (zh) * | 2002-08-26 | 2011-05-25 | 武田药品工业株式会社 | 钙受体调节性化合物及其用途 |
| CA2494700C (en) * | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| DE10360774A1 (de) * | 2003-12-23 | 2005-07-28 | Robert Bosch Gmbh | Verfahren zur Herstellung eines Brennstoffeinspritzventils und Brennstoffeinspritzventil |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| KR20090094336A (ko) | 2006-11-27 | 2009-09-04 | 하. 룬트벡 아크티에 셀스카브 | 헤테로아릴 아미드 유도체 |
| WO2009111700A2 (en) | 2008-03-07 | 2009-09-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| HUE028347T2 (en) | 2008-06-10 | 2016-12-28 | Abbvie Inc | Tricyclic compounds |
| CN102378574B (zh) | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| MX2012000275A (es) * | 2009-07-09 | 2012-02-08 | Raqualia Pharma Inc | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| WO2013010904A1 (en) | 2011-07-15 | 2013-01-24 | Janssen Pharmaceuticals, Inc. | Novel substituted indole derivatives as gamma secretase modulators |
| JP6381445B2 (ja) * | 2011-12-08 | 2018-08-29 | リサーチ トライアングル インスティテュート | ニューロペプチドｓレセプター（ｎｐｓｒ）アンタゴニストの組成物および方法 |
| WO2014122067A1 (en) * | 2013-02-06 | 2014-08-14 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| CN103086955B (zh) | 2013-02-19 | 2014-10-15 | 中国医学科学院医药生物技术研究所 | 3-氨基-4-烷氧亚胺基哌啶的制备方法 |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| CN117645601A (zh) | 2020-06-10 | 2024-03-05 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
| IL299704A (en) | 2020-07-20 | 2023-03-01 | Eccogene Shanghai Co Ltd | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them |
| EP4210680A1 (en) | 2020-09-07 | 2023-07-19 | Cyprumed GmbH | Improved pharmaceutical formulations of glp-1 receptor agonists |
| CN118987224A (zh) | 2020-12-16 | 2024-11-22 | 香港中文大学 | 一种治疗受试者的衰老相关脑功能障碍的组合物及其应用 |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| CN114716423A (zh) | 2022-05-20 | 2022-07-08 | 中国科学院上海药物研究所 | 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途 |
-
2017
- 2017-06-16 JO JOP/2019/0060A patent/JOP20190060A1/ar unknown
- 2017-09-26 UA UAA201902662A patent/UA125586C2/uk unknown
- 2017-09-26 IL IL319036A patent/IL319036A/en unknown
- 2017-09-26 MD MDE20190833T patent/MD3517538T2/ro unknown
- 2017-09-26 PT PT178532206T patent/PT3517538T/pt unknown
- 2017-09-26 JP JP2018540344A patent/JP6567778B2/ja active Active
- 2017-09-26 SI SI201731497T patent/SI3517538T1/sl unknown
- 2017-09-26 PL PL17853220.6T patent/PL3517538T3/pl unknown
- 2017-09-26 IL IL287166A patent/IL287166B2/en unknown
- 2017-09-26 SG SG11201901565VA patent/SG11201901565VA/en unknown
- 2017-09-26 LT LTEPPCT/JP2017/034620T patent/LT3517538T/lt unknown
- 2017-09-26 MY MYPI2019001591A patent/MY199663A/en unknown
- 2017-09-26 EA EA202190802A patent/EA202190802A3/ru unknown
- 2017-09-26 EP EP22180270.5A patent/EP4134367A1/en not_active Withdrawn
- 2017-09-26 MX MX2019003488A patent/MX391309B/es unknown
- 2017-09-26 CN CN201780059135.7A patent/CN109790161B/zh active Active
- 2017-09-26 HR HRP20240499TT patent/HRP20240499T1/hr unknown
- 2017-09-26 KR KR1020197008190A patent/KR102223227B1/ko active Active
- 2017-09-26 MA MA46286A patent/MA46286B1/fr unknown
- 2017-09-26 ES ES17853220T patent/ES2987676T3/es active Active
- 2017-09-26 RS RS20240426A patent/RS65398B1/sr unknown
- 2017-09-26 CR CR20190149A patent/CR20190149A/es unknown
- 2017-09-26 DK DK17853220.6T patent/DK3517538T3/da active
- 2017-09-26 US US18/077,060 patent/USRE50455E1/en active Active
- 2017-09-26 FI FIEP17853220.6T patent/FI3517538T3/fi active
- 2017-09-26 EP EP17853220.6A patent/EP3517538B1/en active Active
- 2017-09-26 US US15/759,872 patent/US10858356B2/en not_active Ceased
- 2017-09-26 TW TW106132936A patent/TWI753946B/zh active
- 2017-09-26 EP EP24154118.4A patent/EP4349840A3/en active Pending
- 2017-09-26 AU AU2017330733A patent/AU2017330733B2/en active Active
- 2017-09-26 HU HUE17853220A patent/HUE066583T2/hu unknown
- 2017-09-26 PE PE2019000705A patent/PE20190709A1/es unknown
- 2017-09-26 EA EA201990518A patent/EA037989B1/ru not_active IP Right Cessation
- 2017-09-26 CA CA3038479A patent/CA3038479C/en active Active
- 2017-09-26 WO PCT/JP2017/034620 patent/WO2018056453A1/ja not_active Ceased
- 2017-09-26 TN TNP/2019/000054A patent/TN2019000054A1/en unknown
-
2019
- 2019-02-19 ZA ZA2019/01070A patent/ZA201901070B/en unknown
- 2019-02-20 IL IL264945A patent/IL264945B/en unknown
- 2019-03-14 CL CL2019000663A patent/CL2019000663A1/es unknown
- 2019-03-20 CO CONC2019/0002595A patent/CO2019002595A2/es unknown
- 2019-03-21 DO DO2019000074A patent/DOP2019000074A/es unknown
- 2019-03-25 SA SA519401409A patent/SA519401409B1/ar unknown
- 2019-03-25 EC ECSENADI201920228A patent/ECSP19020228A/es unknown
- 2019-03-26 MX MX2022004071A patent/MX2022004071A/es unknown
- 2019-03-26 PH PH12019500659A patent/PH12019500659A1/en unknown
- 2019-07-31 JP JP2019141806A patent/JP6957564B2/ja active Active
-
2020
- 2020-08-26 AU AU2020223687A patent/AU2020223687B2/en active Active
- 2020-10-07 US US17/065,122 patent/US11814381B2/en active Active
-
2021
- 2021-10-06 JP JP2021164974A patent/JP7280929B2/ja active Active
-
2022
- 2022-07-13 AU AU2022205222A patent/AU2022205222B2/en active Active
-
2023
- 2023-05-12 JP JP2023079006A patent/JP7602573B2/ja active Active
- 2023-08-11 US US18/448,497 patent/US12187724B2/en active Active
-
2024
- 2024-02-22 US US18/584,672 patent/US12331049B2/en active Active
- 2024-02-22 US US18/584,177 patent/US12410168B2/en active Active
- 2024-03-22 AU AU2024201884A patent/AU2024201884A1/en active Pending
- 2024-08-30 US US18/820,993 patent/US12331050B2/en active Active
- 2024-11-22 US US18/957,166 patent/US20250092041A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190060A1 (ar) | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 | |
| SA521431209B1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
| EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| CL2011000544A1 (es) | Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades. | |
| SG11201805791RA (en) | COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| EP3760195A4 (en) | COMPOSITION WITH 2,3-BUTANEDIOL AS THE ACTIVE SUBSTANCE | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| MX379576B (es) | Derivados de azetidina | |
| EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
| EA202090925A1 (ru) | Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1 | |
| JOP20190054A1 (ar) | مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط | |
| MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
| ES2418032R1 (es) | Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina utiles como inhibidores de receptores sigma | |
| TH1901001721A (th) | อนุพันธ์ไพราโซโลไพริดีนที่มีผลที่มีผลของglp-1รีเซพเตอร์อะโกนิสต์ | |
| PH12019501027A1 (en) | Therapeutic drug or prophylactic drug for diabetic nephropathy | |
| TH1801004568A (th) | อนุพันธ์เฮเทอโรไซคลิคซัลโฟนาไมด์และยาซึ่งมีสารดังกล่าว | |
| TH158992A (th) | อนุพันธ์เบนซิมิดาโซล-โปรลีน | |
| TH1801004478A (th) | ตัวทำการ fxr ที่เป็นสารอนุพันธ์ของสเตอรอยต์ | |
| TH145765A (th) | สารประกอบ ip รีเซพเตอร์ อะโกนิสท์ เฮตเทอโรไซคลิค |